Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.30 |
| ▸ | KDM4A | O75164 | 1/20 | 0.30 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.30 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16682579 | 0.95 | KDM4C (0.36) | PTPN1CA1BLMKDM4CKDM4A | |
| SCHEMBL3929515 | 0.89 | CA1 (0.40) | CA1 | |
| SCHEMBL9633869 | 0.81 | BLM (0.41) | PTPN1BLM | |
| SCHEMBL7714477 | 0.79 | CES1 (0.41) | CA1 | |
| SCHEMBL28191042 | 0.79 | ALDH1A1 (0.33) | — | |
| SCHEMBL4939652 | 0.79 | ALDH1A1 (0.42) | — | |
| SCHEMBL4943737 | 0.79 | CA1 (0.37) | CA1KDM1ABLM | |
| SCHEMBL2304429 | 0.77 | KMT2A (0.45) | PTPN1 | |
| SCHEMBL11515293 | 0.76 | ALDH1A1 (0.37) | — | |
| SCHEMBL2115884 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546603-B2 | Substituted cyclopentanes having prostaglandin activity | ALLERGAN, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120178798-A1 | SUBSTITUTED CYCLOPENTANES HAVING PROSTAGLANDIN ACTIVITY | ALLERGAN, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20090197962-A1 | SUBSTITUTED CYCLOPENTANES HAVING PROSTAGLANDIN ACTIVITY | ALLERGAN, INC. | 2009-08-06 | — | — | US | disclosed |
| US-6265440-B1 | STOMACH ULCERS | R-TECH UENO, LTD. (JP) | 2001-07-24 | — | — | US | disclosed |
| US-5886034-A | ANTIULCER AGENTS | KABUSHIKI KAISHA UENO SEIYAKU KENKYUJO (JP) | 1999-03-23 | — | — | US | disclosed |
| US-5428062-A | Side effect reduction | K.K. UENO SEIYAKU OYO KENKYUJO (JP) | 1995-06-27 | — | — | US | disclosed |
| US-5284858-A | Prostaglandins E and anti ulcers containing same | KABUSHIKI KAISHA UENO SEIYAKU OYO KENKYUJO (JP) | 1994-02-08 | — | — | US | disclosed |
| US-5225439-A | Side effect reduction | K.K. UENO SEIYAKU OYO KENKYUJO (JP) | 1993-07-06 | — | — | US | disclosed |
| US-5166174-A | For duodenal ulcers or gastric ulcers | K.K. UENO SEIYAKU OYO KENKYUJO (JP) | 1992-11-24 | — | — | US | disclosed |
| EP-0284180-B1 | PROSTAGLANDINS E AND ANTI ULCERS CONTAINING SAME | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo (JP) | 1992-08-19 | — | — | EP | disclosed |
| US-5137915-A | PROSTAGLANDINS OF THE D SERIES, AND TRANQUILIZERS AND SOPORIFICS CONTAINING THE SAME | K.K. UENO SEIYAKU OYO KENKYUJO (JP) | 1992-08-11 | — | — | US | disclosed |
| EP-0281239-B1 | PROSTAGLANDINS OF THE D SERIES, AND TRANQUILIZERS AND SOPORIFICS CONTAINING THE SAME | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo (JP) | 1992-03-25 | — | — | EP | disclosed |
| US-5073569-A | 13,14-dihydro-15-keto- | K.K. UENO SEIYAKU OYO KENKYUJO (JP) | 1991-12-17 | — | — | US | disclosed |
| EP-0284180-A1 | Prostaglandins E and anti ulcers containing same | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo (JP) | 1988-09-28 | — | — | EP | disclosed |
| EP-0281239-A2 | Prostaglandins of the D series, and tranquilizers and soporifics containing the same | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo (JP) | 1988-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197962-A1 | SUBSTITUTED CYCLOPENTANES HAVING PROSTAGLANDIN ACTIVITY | PTGIS, PTGES, PTGS1 | PTPN1 3414/4885CA1 1746/4885KDM1A 4413/4885 |
| US-20120178798-A1 | SUBSTITUTED CYCLOPENTANES HAVING PROSTAGLANDIN ACTIVITY | PTGIS, PTGES, PTGS1 | PTPN1 3759/4885CA1 2142/4885KDM1A 4075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.